Patents by Inventor Michael Theisen
Michael Theisen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240148501Abstract: A delivery device includes a catheter, and an inflatable balloon coupled to the catheter, the inflatable balloon forming a leading pillow and a trailing pillow spaced from the leading pillow, the leading pillow and the trailing pillow defining a valve seat therebetween to retain a prosthetic heart valve during tracking of the delivery device.Type: ApplicationFiled: October 31, 2023Publication date: May 9, 2024Applicant: St. Jude Medical, Cardiology Division, Inc.Inventors: Neil Theisen, Michael Shane Morrissey, Tyler Govek, Hannah Thatcher, Hans Rieckmann, Robert Schulzetenberg, Peter J. Ness, Victoria Schuman
-
Publication number: 20240078502Abstract: A system, method, and a package tracking device for tracking the movement of a package to prevent theft of the package are described. According to an embodiment, a package tracking device adapted to be attached with a package is described. The package tracking device having a unique device identification number allows a user, through an application interface running of a wireless communication device, to associate a geographical boundary (geo-fencing) with the delivery address of the package. The package tracking device operates in a passive tracking mode when the package is within the defined geographical boundary, generates a first signal when the package is moved from a drop location, generates a second signal when the package is moved out from the geofencing associated with the delivery address and operates in active tracking mode when the package is moved out from the geofencing associated with the delivery address.Type: ApplicationFiled: March 31, 2023Publication date: March 7, 2024Inventors: Larry Fox, Derrick Gaderson, Jeff Theisen, Michael Geminden
-
Publication number: 20230241194Abstract: Pre-erythrocytic malaria vaccines with good preservation stability and immunostimulatory action are provided. According the present invention, combination use of a pharmaceutical composition comprising (4E,8E,12E,16E,20E)-N-{2-[{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]benzyl}(methyl)amino]ethyl}-4,8,12,17,21,25-hexamethylhexacosa-4,8,12,16,20,24-hexaeneamide, or a pharmaceutically acceptable salt thereof, as a vaccine adjuvant with enhanced specific immune response against antigens and good preservation stability and a malaria vaccine with biological activity allow for the provision of pre-erythrocytic malaria vaccines with good preservation stability and immunostimulatory action.Type: ApplicationFiled: December 1, 2020Publication date: August 3, 2023Inventors: C. Richter King, Yimin Wu, Jordan Lee Plieskatt, Michael Theisen, Susheel Kumar Singh, Akihisa Fukushima
-
Patent number: 11559721Abstract: A cycling device used for exercise and/or rehabilitation includes a shaft for grasping by a user, a foot assembly coupled to the shaft and configured to be supported on a surface, and a pedal assembly coupled between the shaft and the foot assembly. The cycling device is intended to be used by a seated user.Type: GrantFiled: May 4, 2021Date of Patent: January 24, 2023Assignee: WhiteBoard Product SolutionsInventors: Louis Frederick Polk, Paul Michael Theisen
-
Publication number: 20220355161Abstract: A cycling device used for exercise and/or rehabilitation includes a shaft for grasping by a user, a foot assembly coupled to the shaft and configured to be supported on a surface, and a pedal assembly coupled between the shaft and the foot assembly. The cycling device is intended to be used by a seated user.Type: ApplicationFiled: May 4, 2021Publication date: November 10, 2022Inventors: Louis Frederick Polk, Paul Michael Theisen
-
Publication number: 20220194996Abstract: The present invention relates to a method for recombinant production of a fusion protein comprising multiple malaria antigens for inducing immune responses comprising a combination of antibodies. In particular, the fusion proteins of the present invention comprise fragments of both Pfs230 and Pfs48/45 to lower the required threshold of functional antibodies and to reduce the risk of escape mutations. Thus, the fusion proteins of the present invention are suitable for use in a multivalent malaria vaccine.Type: ApplicationFiled: March 30, 2020Publication date: June 23, 2022Inventors: Susheel Kumar Singh, Michael Theisen
-
Publication number: 20190023544Abstract: A heavy-duty lift truck designed as a mast-based apparatus comprising a mast, a load accepting means is mounted on the mast in such a way that it can be raised and lowered, and the heavy-duty lift truck is designed at least for a load capacity of 8 tons, with the heavy-duty lift truck comprising a powertrain with a travel drive that comprises an electric drive unit whereby the heavy-duty lift truck has greater energy efficiency.Type: ApplicationFiled: October 27, 2016Publication date: January 24, 2019Inventors: Mike Hegewald, Lars Michael Theißen, Heinz Ishorst
-
Patent number: 9793178Abstract: The capacity to measure nanoscale features rapidly and accurately is of central importance for the monitoring of manufacturing processes in the production of computer integrated circuits. It is known that far-field scattered light requires a priori sample information in order to reconstruct nanoscale information such as is required in semiconductor metrology. Parameters of interest include, for example, trench depth, duty cycle, wall angle and oxide layer thickness. We describe a scatterometry apparatus and method that uses unconventional polarization states in the pupil of a high NA objective lens, and refer to this as focused beam scatterometry, in which the illumination consists of a focused field with a suitably tailored, spatially-varying polarization distribution. We describe how four or more parameters can be measured and distinguished with an accuracy consistent with the needs laid out in the semiconductor roadmap.Type: GrantFiled: August 24, 2015Date of Patent: October 17, 2017Assignee: University of RochesterInventors: Miguel A. Alonso, Stephen Head, Michael Theisen, Thomas Brown
-
Patent number: 9422348Abstract: The present invention relates to a method for the production of correctly folded Pfs48/45. This is achieved in the lactococcus lactis when Pfs48/45 or fractions thereof are fused genetically to a glutamate rich protein, e.g. GLURP from Plasmodium falciparum.Type: GrantFiled: October 3, 2012Date of Patent: August 23, 2016Inventors: Michael Theisen, Gorm Andersen
-
Publication number: 20160061723Abstract: The capacity to measure nanoscale features rapidly and accurately is of central importance for the monitoring of manufacturing processes in the production of computer integrated circuits. It is known that far-field scattered light requires a priori sample information in order to reconstruct nanoscale information such as is required in semiconductor metrology. Parameters of interest include, for example, trench depth, duty cycle, wall angle and oxide layer thickness. We describe a scatterometry apparatus and method that uses unconventional polarization states in the pupil of a high NA objective lens, and refer to this as focused beam scatterometry, in which the illumination consists of a focused field with a suitably tailored, spatially-varying polarization distribution. We describe how four or more parameters can be measured and distinguished with an accuracy consistent with the needs laid out in the semiconductor roadmap.Type: ApplicationFiled: August 24, 2015Publication date: March 3, 2016Applicant: UNIVERSITY OF ROCHESTERInventors: Miguel A. Alonso, Stephen Head, Michael Theisen, Thomas Brown
-
Patent number: 8889142Abstract: The present invention is related to antigen from Chlamydia trachomatis which are recognized by specific antibodies from individuals infected with Chlamydia or which can induce T cells from the same individuals to secrete gamma-interferon. The T cell reactive antigens are present in a whole-cell lysate and have apparent molecular weights of 5-12, 16-20, 25-35 and 58-74 kDa as determined by SDS-PAGE. The antigens of the invention are believed to be useful in vaccines but also as diagnostic compositions.Type: GrantFiled: October 11, 2005Date of Patent: November 18, 2014Assignee: Statens Serum InstitutInventors: Michael Theisen, Anja Olsen, Robert Leah, Frank Follmann, Klaus Jensen, Peter Andersen
-
Publication number: 20140170182Abstract: The present invention relates to a method for the production of correctly folded Pfs48/45. This is achieved in the lactococcus lactis when Pfs48/45 or fractions thereof are fused genetically to a glutamate rich protein, e.g. GLURP from Plasmodium falciparum.Type: ApplicationFiled: October 3, 2012Publication date: June 19, 2014Applicant: STATENS SERUM INSTITUTInventors: Michael Theisen, Gorm Andersen
-
Publication number: 20110020387Abstract: A fusion protein, from P. falciparum Glutamate-rich protein (GLURP) genetically coupled to P. falciparum Merozoite surface protein 3 (MSP3) was produced in Lactococcus lactis as a secreted recombinant GLURP-MSP3 hybrid protein and experiments showed that the GLURP-part of the hybrid increased the overall antibody response. Immunizations with the hybrid protein consistently generated a stronger antibody response against the individual GLURP and MSP3 domains than a mixture of the two recombinant molecules injected at one site or the individual recombinant molecules injected simultaneously at two different sites. The difference was most pronounced for the MSP3-specific antibody response suggesting that T cell epitopes located in the GLURP RO-region provide help for B-cell epitopes in the MSP3 region.Type: ApplicationFiled: June 3, 2010Publication date: January 27, 2011Applicant: STATENS SERUM INSTITUTInventors: MICHAEL THEISEN, SØREN JEPSEN
-
Patent number: 7749507Abstract: A fusion protein, derived from P. falciparum Glutamate-rich protein (GLURP) genetically coupled to P. falciparum Merozoite surface protein 3 (MSP3) was produced in Lactococcus lactis as a secreted recombinant GLURP-MSP3 hybrid protein and experiments showed that the GLURP-part of the hybrid increased the overall antibody response. Immunizations with the hybrid protein consistently generated a stronger antibody response against the individual GLURP and MSP3 domains than a mixture of the two recombinant molecules injected at one site or the individual recombinant molecules injected simultaneously at two different sites. The difference was most pronounced for the MSP3-specific antibody response suggesting that T cell epitopes located in the GLURP RO-region provide help for B-cell epitopes in the MSP3 region.Type: GrantFiled: May 12, 2005Date of Patent: July 6, 2010Assignee: Statens Serum InstitutInventors: Michael Theisen, Søren Jepsen
-
Publication number: 20090304722Abstract: The present invention is related to antigens from Chlamydia trachomatis which are recognized by specific antibodies from individuals infected with Chlamydia or which can induce T cells from the same individuals to secrete gamma-interferon. The T cell reactive antigens are present in a whole-cell lysate and have apparent molecular weights of 5-12, 16-20, 25-35 and 58-74 kDa as determined by SDS-PAGE. The antigens of the invention are useful in vaccines but also as diagnostic compositions.Type: ApplicationFiled: October 11, 2005Publication date: December 10, 2009Inventors: Michael Theisen, Anja Olsen, Robert Leah, Frank Follmann, Klaus Jensen, Peter Andersen
-
Publication number: 20060024324Abstract: A fusion protein, from P. falciparum Glutamate-rich protein(GLURP) genetically coupled to P. falciparum Merozoite surface protein 3 (MSP3) was produced in Lactococcus lactis as a secreted recombinant GLURP-MSP3 hybrid protein and experiments showed that the GLURP-part of the hybrid increased the overall antibody response. Immunizations with the hybrid protein consistently generated a stronger antibody response against the individual GLURP and MSP3 domains than a mixture of the two recombinant molecules injected at one site or the individual recombinant molecules injected simultaneously at two different sites. The difference was most pronounced for the MSP3-specific antibody response suggesting that T cell epitopes located in the GLURP RO-region provide help for B-cell epitopes in the MSP3 region.Type: ApplicationFiled: May 12, 2005Publication date: February 2, 2006Inventors: Michael Theisen, Soren Jepsen
-
Publication number: 20040204294Abstract: Exercise apparatus for exercising the upper body simultaneously with lower body exercise, comprising a lower body exercise machine and at least one upper body exercise module positioned for use in conjunction with the lower body exercise machine. The upper body exercise module comprises an elongated connector having first and second ends; a user engagement connected to the elongated connector first end for engaging or being engaged by a body appendage of a user; and a resistance mechanism for resisting a force applied to the first end of the elongated connector. Each upper body exercise module is adapted to provide resistance to a full, natural arm swing of at least one arm of the user. Various types of lower body exercise machines, resistance devices, user engagements, relationships between the upper body exercise module and the lower body exercise machine, and exercise methods using the apparatus are disclosed.Type: ApplicationFiled: July 1, 2003Publication date: October 14, 2004Inventors: William T Wilkinson, Paul Michael Theisen, Micah Tobias Somers
-
Publication number: 20040086949Abstract: The present invention relates to a method for preparing a ligand presenting assembly (LPA), an LPA, an immunological composition and a vaccine. The invention further relates to a method for generating antibodies, a kit for use in diagnosis and use of an LPA for preparing a pharmaceutical composition.Type: ApplicationFiled: December 1, 2003Publication date: May 6, 2004Applicant: Statens Serum InstitutInventors: Arne Holm, Rikke Malene Jorgensen, Soren Ostergaard, Michael Theisen
-
Patent number: 6716574Abstract: A diagnostic method is disclosed which utilizes short C-terminal fragments of Borrelia burgdorferi sensu lato derived protein OspC. The 4 amino-terminal acids Pro-Lys-Pro (SEQ ID NO: 22) are shown to be essential in immune reactivity between sera from patients suffering from early borreliosis and various OspC derivatives and it is shown that in order to be effective as a diagnostic agent, 5 consecutive amino acid residues long homologue of a fragment identical to the 10 C-terminal amino acids of OspC (SEQ DI NO: 1). Also disclosed are vaccines utilizing the short peptides as well as methods for their preparation.Type: GrantFiled: October 10, 2001Date of Patent: April 6, 2004Assignee: Dako A/SInventors: Marianne Jartved Mathiesen, Michael Theisen, Arne Holm, Søren Østergaard
-
Patent number: D740084Type: GrantFiled: May 20, 2014Date of Patent: October 6, 2015Assignee: CleanCut Solutions LLCInventors: Anthony L. Schmitt, Michael Theisen